Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.
2.

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci.

Clark J, Fung-Tomc JC, Minassian B, Tsai YH, Yang H, Huczko E, Kolek B, Chaniewski S, Ferraro C, Drain R, Gradelski E, Bonner DP.

Antimicrob Agents Chemother. 2002 Apr;46(4):1108-11.

3.

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci.

Fung-Tomc JC, Clark J, Minassian B, Pucci M, Tsai YH, Gradelski E, Lamb L, Medina I, Huczko E, Kolek B, Chaniewski S, Ferraro C, Washo T, Bonner DP.

Antimicrob Agents Chemother. 2002 Apr;46(4):971-6.

4.

Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.

Fung-Tomc J, Gradelski E, Huczko E, Minassian B, Bonner DP.

Int J Antimicrob Agents. 2001 Jul;18(1):77-80.

PMID:
11463531
5.

Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.

Gradelski E, Kolek B, Bonner DP, Valera L, Minassian B, Fung-Tomc J.

Int J Antimicrob Agents. 2001 Feb;17(2):103-7.

PMID:
11165113
6.

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, Washo T, Gradelski E, Valera L, Bonner DP.

Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6.

7.

Comparative killing rates of fluoroquinolones and cell wall-active agents.

Fung-Tomc JC, Gradelski E, Valera L, Kolek B, Bonner DP.

Antimicrob Agents Chemother. 2000 May;44(5):1377-80.

8.

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole.

Fung-Tomc JC, White TC, Minassian B, Huczko E, Bonner DP.

Diagn Microbiol Infect Dis. 1999 Oct;35(2):163-7.

PMID:
10579098
9.

In vitro activity of a new oral triazole, BMS-207147 (ER-30346)

Fung-Tomc JC, Huczko E, Minassian B, Bonner DP.

Antimicrob Agents Chemother. 1998 Feb;42(2):313-8. Erratum in: Antimicrob Agents Chemother 1998 Apr;42(4):993.

10.

Recent developments in pradimicin-benanomicin and triazole antibiotics.

Fung-Tomc JC, Bonner DP.

Expert Opin Investig Drugs. 1997 Feb;6(2):129-45.

PMID:
15989596
11.

Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1996 May;40(5):1289-93.

12.

Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.

Fung-Tomc JC, Huczko E, Banville J, Ménard M, Kolek B, Gradelski E, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):394-9.

13.

Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Fung-Tomc JC, Gradelski E, Kolek B, Minassian B, Pucci M, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):386-93.

14.

In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.

Kessler RE, Fung-Tomc J, Kolek B, Minassian B, Huczko E, Gradelski E, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):380-5.

15.

In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.

Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE.

Antimicrob Agents Chemother. 1995 Feb;39(2):295-300.

17.

beta-Lactamase parameters of heterogeneously and homogeneously methicillin-resistant Staphylococcus aureus.

Gradelski E, Huczko E, Kessler RE, Bonner DP, Fung-Tomc J.

J Antimicrob Chemother. 1993 Mar;31(3):441-2. No abstract available.

PMID:
8486580
18.

Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.

McCullough JE, Muller MT, Howells AJ, Maxwell A, O'Sullivan J, Summerill RS, Parker WL, Wells JS, Bonner DP, Fernandes PB.

J Antibiot (Tokyo). 1993 Mar;46(3):526-30. No abstract available.

19.

Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays.

Mamber SW, Kolek B, Brookshire KW, Bonner DP, Fung-Tomc J.

Antimicrob Agents Chemother. 1993 Feb;37(2):213-7.

20.

Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.

Soike K, Huang JL, Tu JI, Stouffer B, Mitroka JG, Swerdel M, Olsen S, Bonner DP, Tuomari AV, Field AK.

J Infect Dis. 1992 Apr;165(4):732-6.

PMID:
1313071
21.

Emergence of homogeneously methicillin-resistant Staphylococcus aureus.

Fung-Tomc J, Huczko E, Gradelski E, Denbleyker K, Bonner DP, Kessler RE.

J Clin Microbiol. 1991 Dec;29(12):2880-3.

22.

Tissue distribution of amphotericin B lipid complex in laboratory animals.

Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP.

J Pharm Pharmacol. 1991 Dec;43(12):831-5.

PMID:
1687580
23.
24.

Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice.

Braitman A, Swerdel MR, Olsen SJ, Tuomari AV, Lynch JS, Blue B, Michalik T, Field AK, Bonner DP, Clark JM.

Antimicrob Agents Chemother. 1991 Jul;35(7):1464-8.

25.

Amphotericin B lipid complex therapy of experimental fungal infections in mice.

Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP.

Antimicrob Agents Chemother. 1991 Apr;35(4):615-21.

26.
27.

The versatile monobactam family: new agents addressing specific needs in infectious disease.

Bonner DP, Koster WH.

J Chemother. 1989 Jul;1(4 Suppl):133-4. No abstract available.

PMID:
16312338
28.

The versatile monobactam family: manipulation of intrinsic activity and in vivo efficacy via N-1 activating group modification.

Koster WH, Bonner DP, Zahler R.

J Chemother. 1989 Jul;1(4 Suppl):116-8. No abstract available.

PMID:
16312331
29.

Inactivation of beta-lactamases from Enterobacter cloacae by monophosphams.

Bush K, Smith SA, Tanaka SK, Bonner DP.

J Antimicrob Chemother. 1988 Dec;22(6):801-9.

PMID:
3266620
30.

Lysobactin, a novel antibacterial agent produced by Lysobacter sp. II. Biological properties.

Bonner DP, O'Sullivan J, Tanaka SK, Clark JM, Whitney RR.

J Antibiot (Tokyo). 1988 Dec;41(12):1745-51.

31.

The new monobactams: chemistry and biology.

Sykes RB, Koster WH, Bonner DP.

J Clin Pharmacol. 1988 Feb;28(2):113-9.

PMID:
3360965
32.

Improved sensitivity in assays for binding of novel beta-lactam antibiotics to penicillin-binding proteins of Escherichia coli.

Bush K, Smith SA, Ohringer S, Tanaka SK, Bonner DP.

Antimicrob Agents Chemother. 1987 Aug;31(8):1271-3.

33.

In vivo evaluation of tigemonam, a novel oral monobactam.

Clark JM, Olsen SJ, Weinberg DS, Dalvi M, Whitney RR, Bonner DP, Sykes RB.

Antimicrob Agents Chemother. 1987 Feb;31(2):226-9.

34.

In vitro evaluation of tigemonam, a novel oral monobactam.

Tanaka SK, Summerill RA, Minassian BF, Bush K, Visnic DA, Bonner DP, Sykes RB.

Antimicrob Agents Chemother. 1987 Feb;31(2):219-25.

35.

Evaluation of aztreonam, cefoperazone, latamoxef and ceftazidime in the hamster colitis model.

Weinberg DS, Fernandes PB, Kao CC, Clark JM, Bonner DP, Sykes RB.

J Antimicrob Chemother. 1986 Dec;18(6):729-45.

PMID:
3546243
36.

Aztreonam: preclinical studies.

Bonner DP, Tanaka SK, Schwind RA.

N J Med. 1986 Jan;Spec No:20-5. No abstract available.

PMID:
3456495
37.

Discovery and development of the monobactams.

Sykes RB, Bonner DP.

Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S579-93. Review.

PMID:
3909315
38.

Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae.

Bush K, Tanaka SK, Bonner DP, Sykes RB.

Antimicrob Agents Chemother. 1985 Apr;27(4):555-60.

39.

Aztreonam: the first monobactam.

Sykes RB, Bonner DP.

Am J Med. 1985 Feb 8;78(2A):2-10.

PMID:
3871589
40.

Modern beta-lactam antibiotics.

Sykes RB, Bonner DP, Swabb EA.

Pharmacol Ther. 1985;29(3):321-52. Review. No abstract available.

PMID:
3915359
41.

Structure activity relationships among the monobactams.

Bonner DP, Sykes RB.

J Antimicrob Chemother. 1984 Oct;14(4):313-27. Review.

PMID:
6389473
42.

Counteracting antibiotic resistance: new drugs.

Sykes RB, Bonner DP.

Br Med Bull. 1984 Jan;40(1):96-101. Review. No abstract available.

PMID:
6398730
43.

Prediction of aztreonam pharmacokinetics in humans based on data from animals.

Swabb EA, Bonner DP.

J Pharmacokinet Biopharm. 1983 Jun;11(3):215-23.

PMID:
6685766
44.

Aztreonam: a new concept in beta-lactam antibiotics.

Fernandes PB, Bonner DP, Sykes RB.

Compr Ther. 1983 May;9(5):21-6. No abstract available.

PMID:
6682744
45.

Distribution of beta-lactam and beta-lactone producing bacteria in nature.

Wells JS, Hunter JC, Astle GL, Sherwood JC, Ricca CM, Trejo WH, Bonner DP, Sykes RB.

J Antibiot (Tokyo). 1982 Jul;35(7):814-21.

46.

Penicillin-binding proteins in a Staphylococcus aureus strain resistant to specific beta-lactam antibiotics.

Georgopapadakou NH, Smith SA, Bonner DP.

Antimicrob Agents Chemother. 1982 Jul;22(1):172-5.

47.

EM5400, a family of monobactam antibiotics produced by Agrobacterium radiobacter. I. Taxonomy, fermentation and biological properties.

Wells JS, Trejo WH, Principe PA, Bush K, Georgopapadakou N, Bonner DP, Sykes RB.

J Antibiot (Tokyo). 1982 Mar;35(3):295-9. No abstract available.

48.

SQ 26,180, a novel monobactam. I Taxonomy, fermentation and biological properties.

Wells JS, Trejo WH, Principe PA, Bush K, Georgopapadakou N, Bonner DP, Sykes RB.

J Antibiot (Tokyo). 1982 Feb;35(2):184-8.

49.

Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Sykes RB, Bonner DP, Bush K, Georgopapadakou NH.

Antimicrob Agents Chemother. 1982 Jan;21(1):85-92.

50.

In-vivo properties of SQ 26,776.

Bonner DP, Whitney RR, Baughn CO, Miller BH, Olsen SJ, Sykes RB.

J Antimicrob Chemother. 1981 Dec;8 Suppl E:123-30. No abstract available.

PMID:
6976961

Supplemental Content

Loading ...
Support Center